Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
RegulatoryapprovedJideytroPositive
AI Analysis
Summary
GlaxoSmithKline received FDA approval for Jideytro (zidesamtinib) for previously treated ROS1-positive non-small cell lung cancer, based on positive results from the ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or metastatic disease.
Clinical Trial Data
Phase
I/II
Primary Endpoint
Met
Outcome Details
FDA approval for previously treated ROS1-positive non-small cell lung cancer based on ARROS-1 phase I/II trial
Importance:8/10
Sentiment:
0.85
FDA approvaloncologylung cancerROS1-positiveNSCLC
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 22, 2026 5:58 PM